Scott Dworkin says the CDC's Ebola contract with XpresTest was 'NOT COMPETED' and has since grown

Scott DworkinPolitical commentator and writer of The Dworkin Report, in his Substack newsletter

Condemned

In his November 13 newsletter, Dworkin says ProPublica's report is the kind of thing Congress should examine. He disputes the XWELL chief executive's account of competitive bidding, citing the CDC contract record, and says a November 6 addition of $16.7 million brings the company's awards to $55.5 million.

Responding to

XpresTest won its CDC Ebola entry screening contract and its State Department outbreak response award through competitive bidding.

“ProPublica showed this week exactly the type of thing Congress should be looking at. In February, an investment fund linked to Trump’s sons put about $30 million into a company called XWELL. Months later, the regime handed XWELL’s testing business nearly $40 million in contracts to screen for Ebola and other diseases. A spokesperson for Trump’s sons told ProPublica they are passive investors who had no involvement in the contracts. XWELL’s CEO told ProPublica the company won through competitive bidding. So I pulled the CDC contract’s records myself. They say “NOT COMPETED.” Only one offer came in. Then on November 6, the CDC chose to put $16.7 million more into the same contract. That money isn’t in the figure reported this week. It brings the total to $55.5 million.”

Original text

Read the original text (opens in a new tab)Trump Is Running Out Of People Who Are Afraid Of Him · Scott DworkinSection on Rep. Robert Garcia and the XWELL contracts

Original text

Read the original text (opens in a new tab)Federal Procurement Data System records for CDC contract 75D30126C21193 with XpresTest Inc.Modification P00003, signed November 6, 2026

Reporting

Open source (opens in a new tab)ProPublica report on XpresTest's nearly $40 million in federal Ebola screening awards and its parent company's ties to Trump's sons · ProPublicaFull article

Case updates

Want the next important update?

Follow this case and get an email when an important development changes the record.

Important updates only. Free. Confirm your email to start. Unsubscribe anytime. How we handle your email.

A U.S. Coast Guard corpsman in a face shield, mask and blue gloves holds a thermometer up to a traveler, who is seen from behind, while another masked officer looks on.
Credit: Josh Denmark / U.S. Customs and Border Protection

Where this statement fits

XpresTest won more than $55 million in Ebola awards months after a fund tied to Trump's sons invested in its parent; the sons say they had no role

On November 9, 2026, ProPublica reported that XpresTest, the biosurveillance subsidiary of XWELL Inc., received an $18.8 million CDC contract to screen travelers for Ebola at U.S. airports and a $20 million State Department award for outbreak response in the Democratic Republic of Congo. Both came months after American Ventures, a fund launched by Dominari Holdings, invested about $30 million in XWELL. Dominari hired Donald Trump Jr. and Eric Trump as advisers and gave them a stake of more than 10%, according to ProPublica. XWELL's chief executive, Ezra Ernst, told ProPublica that XpresTest won both awards in competitive bidding. The federal award record for the CDC contract lists it as not competed, with one offer received, under the urgency exception in FAR 6.302-2. A modification signed November 6 exercises an option on that contract and brings its total obligations to $35.5 million, according to the federal procurement record. The State Department says its award was competitive. A spokesperson for the Trump sons says they are passive minority investors in the fund and had no involvement in the contracts.

Read the full case

Source and context

Original text

Trump Is Running Out Of People Who Are Afraid Of Him (opens in a new tab) · Scott DworkinSection on Rep. Robert Garcia and the XWELL contracts

About this source

An edition of Dworkin's newsletter, The Dworkin Report, on congressional Democrats' oversight plans. One section discusses ProPublica's XWELL report and the federal procurement record for the CDC's Ebola screening contract with XpresTest.

Original text

Federal Procurement Data System records for CDC contract 75D30126C21193 with XpresTest Inc. (opens in a new tab)Modification P00003, signed November 6, 2026

About this source

The federal procurement record for the CDC's Ebola entry screening contract with XpresTest lists the original award of July 6, 2026 and three modifications. Modification P00003, signed November 6, 2026, exercises an option and obligates $16,720,916, bringing total obligations to $35,536,326.68. Each entry lists the contract as not competed under the urgency exception, with one offer received.

Reporting

ProPublica report on XpresTest's nearly $40 million in federal Ebola screening awards and its parent company's ties to Trump's sons (opens in a new tab) · ProPublicaFull article

About this source

ProPublica reports that XpresTest, a subsidiary of XWELL, received an $18.8 million CDC contract for Ebola entry screening at U.S. airports and a $20 million State Department award for outbreak response in the Democratic Republic of Congo, months after American Ventures, a fund launched by Dominari Holdings, invested about $30 million in XWELL. It includes responses from the State Department, a spokesperson for Donald Trump Jr. and Eric Trump, Dominari's chief executive and XWELL's chief executive.

Archived copy (opens in a new tab)

Before the quotation

The passage follows Dworkin's account of warnings that Trump administration lawyers sent that week to Rep. Robert Garcia, the top Democrat on the House Oversight Committee, and Sen. Richard Blumenthal over their investigations.

After the quotation

The federal procurement record lists the CDC contract as not competed under the urgency exception, with one offer received, and shows a November 6 option exercise of $16,720,916 that brings its total obligations to $35,536,326.68. ProPublica reports that the State Department award was $20 million and that the State Department says it was made through a competitive process.

How this statement is classified

Condemned

The label describes this statement's response within the context above.

Why this label?

Dworkin presents the awards as a matter for congressional oversight and uses the contract record to dispute the company's account that it won them through competitive bidding, so we labeled it Condemned.

Recorded on
Published here
People and groups discussed
XWELL, Inc., Centers for Disease Control and Prevention

More from this case

Read the full case

Eric Trump calls the XpresTest report 'an absolutely fake story' and says he will sue ProPublica

Eric Trump

“This is an absolutely fake story as usual—one of about 20 I have seen targeting anyone and everything Trump this week. A legal letter and my intent to sue ProPublica have already been issued (see below). Two minutes of research shows that this company’s relationship with the CDC occurred in 2021, under the Biden Administration. I have nothing to do with this company other than being a passive investor in an entity that has a minority interest. I have never spoken to them; I don’t know anybody from their management team, what they do, or who they are. Nothing. This is slander, and I will hold anyone— which will start with ProPublica—who suggests otherwise liable.”
Read statement

Share or embed this statement

Quote card: Scott Dworkin, Scott Dworkin says the CDC's Ebola contract with XpresTest was 'NOT COMPETED' and has since grownDownload image (PNG)

The embed keeps its attribution link to The Dispute Index. Credit the image to The Dispute Index and link to the statement page.

Cite this record

Publisher
The Dispute Index
Title
Scott Dworkin says the CDC's Ebola contract with XpresTest was 'NOT COMPETED' and has since grown
First published
Last updated
Permalink
https://disputeindex.com/events/9091-in-his-november-13-newsletter-dworkin-says-propublica

Last updated marks the most recent saved version of this published statement.

The Dispute Index. "Scott Dworkin says the CDC's Ebola contract with XpresTest was 'NOT COMPETED' and has since grown". First published: 2026-11-15. Last updated: 2026-11-15. https://disputeindex.com/events/9091-in-his-november-13-newsletter-dworkin-says-propublica